Seizure Prophylaxis in Patients with Traumatic Brain Injury: A Single-Center Study

Shannon Inglet1, Margaret Baldwin1, Amie H Quinones1

  • 1Department of Pharmacy, Intermountain Medical Center.

Cureus
|October 1, 2016
PubMed

Insights

Prophylactic anticonvulsants for traumatic brain injury (TBI) patients may reduce early post-traumatic seizures (PTSs). However, prophylaxis was linked to higher mortality and longer hospital stays in this study.

Area of Science:

  • Neurology
  • Trauma Surgery
  • Clinical Pharmacology

Background:

  • Prophylactic anticonvulsants are recommended for preventing early post-traumatic seizures (PTSs) in traumatic brain injury (TBI) patients.
  • However, their administration is inconsistent in clinical practice.

Purpose of the Study:

  • To evaluate the outcomes associated with seizure prophylaxis in patients with TBI.
  • To analyze the incidence of early PTSs, mortality, length of stay, and late seizures in relation to prophylaxis administration.

Main Methods:

  • Retrospective cohort study including 2,111 TBI patients admitted to a Level 1 trauma center.
  • Data collected from October 2007 to May 2012.
  • Comparison of outcomes between patients who received seizure prophylaxis and those who did not.

Main Results:

  • Two early PTSs occurred in the prophylaxis group (0.4%) versus 21 in the non-prophylaxis group (1.4%) (p = 0.05).
  • The prophylaxis group had a higher mortality rate (14.2% vs. 6.2%; p < 0.001) and longer hospital length of stay (LOS) (6.8 vs. 3.8 days; p < 0.001).
  • Patients receiving prophylaxis often had lower Glasgow Coma Scale (GCS) scores and more severe injuries, including brain hemorrhage.

Conclusions:

  • Seizure prophylaxis was associated with a lower incidence of early PTSs in TBI patients.
  • However, prophylaxis administration correlated with increased mortality and longer hospital LOS, likely reflecting more severe initial injuries in this group.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.0K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
895